Stay updated on Dabrafenib, Trametinib, Spartalizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Dabrafenib, Trametinib, Spartalizumab in Melanoma Clinical Trial page.

Latest updates to the Dabrafenib, Trametinib, Spartalizumab in Melanoma Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference6%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.3%
- Check45 days agoChange DetectedThe web page has updated its version from v2.14.4 to v2.15.0, indicating a revision in the content. The phrase 'Here’s how you know' has been removed and replaced with a similar phrase.SummaryDifference1.0%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
- Check96 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check110 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
Stay in the know with updates to Dabrafenib, Trametinib, Spartalizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dabrafenib, Trametinib, Spartalizumab in Melanoma Clinical Trial page.